Visiongain has published a new report on Neurotrophic Keratitis Market Report 2021-2031: Forecasts By Treatment (Drugs, Devices, and Surgical Intervention) By Stage (Stage I, Stage II, and Stage III), By Route of Administration (Topical, and Oral), By Patient Demographics (Geriatric Patient, Adult Patient, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, Academic and Research Institute, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.

Global Neurotrophic Keratitis market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Neurotrophic Keratitis market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.

COVID-19 Impact on Neurotrophic Keratitis Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Neurotrophic Keratitis market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:

Market Drivers

Increasing Prevalence of Neurotrophic Keratitis

Neurotrophic keratitis is a corneal degenerative disease which is categorized as an absence or reduction of corneal sensitivity. Neurotrophic keratitis causes complete or partial loss of corneal sensation which might result in epithelial defect, stromal ulceration, epithelial keratopathy, and eventually corneal perforation. Neurotrophic keratitis prevalence is increasing very significantly as compared to the last few years and it is expected that neurotrophic keratitis prevalence will increase during the forecast period. Increasing neurotrophic keratitisr cases creates a huge demand for the treatment of neurotrophic Keratitis. Due to the Increasing prevalence of neurotrophic keratitisr is working as a driver for the neurotrophic keratitisr market.

Increasing Strategic initiatives in Neurotrophic Keratitis
Neurotrophic keratitis market is recording various strategic initiatives form the player present in the market and from the manufactures is planning to enter in the market. Manufactures in the market have formed various partnerships and joint ventures, mergers & acquisitions to launch new products and acquired new regulatory approvals. These strategic initiatives have increased their revenue generation and helped manufacture to increase their market share in neurotrophic keratitis in the market.

Market Opportunities

Increasing focus on Healthcare Infrastructure
National and international organizations & authorities from all over the world are increasing their focus on development and strengthening of healthcare infrastructure. Authorities are taking necessary steps to, modify and strategize healthcare infrastructure and advance medication development and delivery. Increasing focus on healthcare infrastructure and advance medication development has facilitated various manufactures with special status and tentative approval for new drug developments which is expected to increase number of medication in the market and to create new opportunities for neurotrophic keratitis market,

Competitive Landscape

Top companies (Dompe farmaceutici S.p.A., Allergan, ReGenTree, LLC, and Alcon,) constitute more than XX% share of the global Neurotrophic Keratitis market. Other companies profiled in the report include: Bausch & Lomb Incorporated (Bausch Health Companies Inc.), CONTACARE, OHTO Pharmaceutical Co., Ltd., Pfizer, Inc., Santen Pharmaceutical Co., Ltd., Johnson & Johnson and Other Company among) others Some of the key developments are listed below:

● In 2018, Dompé Farmaceutici S.p.A.have received U.S. Food and Drug Administration (FDA) approval for cenegermin which is an eye drop, first-in-class recombinant human nerve growth factor to heal rare neurotrophic keratitis. The approval is expected to help the company to its market share in the Neurotrophic Keratitis market.
● In 2018, Sanofi launched Aubagio (teriflunomide, 14 mg) in India. Aubagio is a ‘once-daily’ oral ‘disease modifying therapy’ (DMT) for treatment of multiple sclerosis disease. With the launch of a new drug for treatment of multiple sclerosis disease the company is expected to increase their market presence in the Neurotrophic Keratitis market.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.